Publications 2024

Haakensen VD, Öjlert ÅK, Thunold S, Farooqi S, Nowak AK, Chin WL, Grundberg O, Szejniuk WM, Cedres S, Sørensen JB, Dalen TS, Lund-Iversen M, Bjaanæs M, Helland Å (2024)
UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma - A phase II randomised trial
Eur J Cancer, 202, 113973
DOI 10.1016/j.ejca.2024.113973, PubMed 38447379

Thunold S, Hernes E, Farooqi S, Öjlert ÅK, Francis RJ, Nowak AK, Szejniuk WM, Nielsen SS, Cedres S, Perdigo MS, Sørensen JB, Meltzer C, Mikalsen LTG, Helland Å, Malinen E, Haakensen VD (2024)
Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccine
Eur J Nucl Med Mol Imaging (in press)
DOI 10.1007/s00259-024-06853-0, PubMed 39133306

Publications 2021

Farooqi SJ, Bjaanæs MM, Helland Å, Haakensen VD (2021)
[Immunotherapy for malignant pleural mesothelioma]
Tidsskr Nor Laegeforen, 141
DOI 10.4045/tidsskr.21.0503, PubMed 34505475

Farooqi SJ, Helland A, Haakensen VD, Bjaanaes MM (2021)
Immunotherapy in malignant pleural mesothelioma
Tidsskr. Nor. Laegeforen., 141 (12), 1167-1169

Haakensen VD, Nowak AK, Ellingsen EB, Farooqi SJ, Bjaanæs MM, Horndalsveen H, Mcculloch T, Grundberg O, Cedres SM, Helland Å (2021)
NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma
J Transl Med, 19 (1), 232
DOI 10.1186/s12967-021-02905-3, PubMed 34059094